Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5F3N2O2 |
| Molecular Weight | 206.122 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
InChI
InChIKey=UTKUVRNVYFTEHF-UHFFFAOYSA-N
InChI=1S/C7H5F3N2O2/c8-7(9,10)5-3-4(11)1-2-6(5)12(13)14/h1-3H,11H2
4-Nitro-3-trifluoromethylaniline is one of the two main products of flutamide metabolism in human liver microsomes. Also, it is a major urinary metabolite of S-1 [3-(4-fluorophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide] - a member of a series of potent selective androgen receptor modulators.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Glutathione Sources: https://www.ncbi.nlm.nih.gov/pubmed/18411402 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Microbial metabolism. Part 11. Metabolites of flutamide. | 2010-04 |
|
| Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. | 2009-07 |
|
| Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. | 2009-01 |
|
| Bioactivation of flutamide metabolites by human liver microsomes. | 2008-07 |
|
| Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites. | 2007-10 |
|
| Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry. | 2006-06 |
|
| Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. | 2006-05 |
|
| Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. | 2006-03 |
|
| Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. | 2003-10 |
|
| Hydrogen bonding in C-substituted nitroanilines: molecular ladders in 2-trifluoromethyl-4-nitroaniline and sheets of R(4)(4)(12) and R(4)(4)(32) rings in 3-trifluoromethyl-4-nitroaniline. | 2002-02 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18832480
Mice: 200 mg/kg for 5 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18411402
4-Nitro-3-trifluoromethylaniline (Flu-1) (5–100 uM) was incubated for 1 h at 37°C in an incubation system, consisting of 100 mM potassium phosphate buffer (pH 7.4), 2 mg of human liver microsomes, 5 mM of reduced glutathione (GSH), and 1 mM NADPH in a final volume of 1 ml. Two adducts (Flu-1-G1 AND Flu-1-G2) were identified and characterized.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
15YY91105I
Created by
admin on Mon Mar 31 21:30:11 GMT 2025 , Edited by admin on Mon Mar 31 21:30:11 GMT 2025
|
PRIMARY | |||
|
1285997
Created by
admin on Mon Mar 31 21:30:11 GMT 2025 , Edited by admin on Mon Mar 31 21:30:11 GMT 2025
|
PRIMARY | |||
|
206-884-6
Created by
admin on Mon Mar 31 21:30:11 GMT 2025 , Edited by admin on Mon Mar 31 21:30:11 GMT 2025
|
PRIMARY | |||
|
DTXSID7057731
Created by
admin on Mon Mar 31 21:30:11 GMT 2025 , Edited by admin on Mon Mar 31 21:30:11 GMT 2025
|
PRIMARY | |||
|
10323
Created by
admin on Mon Mar 31 21:30:11 GMT 2025 , Edited by admin on Mon Mar 31 21:30:11 GMT 2025
|
PRIMARY | |||
|
94955
Created by
admin on Mon Mar 31 21:30:11 GMT 2025 , Edited by admin on Mon Mar 31 21:30:11 GMT 2025
|
PRIMARY | |||
|
393-11-3
Created by
admin on Mon Mar 31 21:30:11 GMT 2025 , Edited by admin on Mon Mar 31 21:30:11 GMT 2025
|
PRIMARY |
PARENT (METABOLITE)
SUBSTANCE RECORD